BACKGROUND: Methamphetamine (MA) use has been linked anecdotally to rampant dental disease. The authors sought to determine the relative prevalence of dental comorbidities in MA users, verify whether MA users have more quantifiable dental disease and report having more dental problems than nonusers and establish the influence of mode of MA administration on oral health outcomes. METHODS: Participating physicians provided comprehensive medical and oral assessments for adults dependent on MA (n=301). Trained interviewers collected patients' self-reports regarding oral health and substance-use behaviors. The authors used propensity score matching to create a matched comparison group of nonusers from participants in the the Third National Health and Nutrition Examination Survey (NHANES III). RESULTS: Dental or oral disease was one of the most prevalent (41.3 percent) medical cormorbidities in MA users who otherwise were generally healthy. On average, MA users had significantly more missing teeth than did matched NHANES III control participants (4.58 versus 1.96, P<.001) and were more likely to report having oral health problems (P<.001). Significant subsets of MA users expressed concerns with their dental appearance (28.6 percent), problems with broken or loose teeth (23.3 percent) and tooth grinding (bruxism) or erosion (22.3 percent). The intravenous use of MA was significantly more likely to be associated with missing teeth than was smoking MA (odds ratio=2.47; 95 percent confidence interval=1.3-4.8). CONCLUSIONS: Overt dental disease is one of the key distinguishing comorbidities in MA users. MA users have demonstrably higher rates of dental disease and report long-term unmet oral health needs. Contrary to common perception, users who smoke or inhale MA have lower rates of dental disease than do those who inject the drug. Many MA users are concerned with the cosmetic aspects of their dental disease, and these concerns could be used as behavioral triggers for targeted interventions. CLINICAL IMPLICATIONS: Dental disease may provide a temporally stable MA-specific medical marker with discriminant utility in identifying MA users. Dentists can play a crucial role in the early detection of MA use and participate in the collaborative care of MA users.
BACKGROUND:Methamphetamine (MA) use has been linked anecdotally to rampant dental disease. The authors sought to determine the relative prevalence of dental comorbidities in MA users, verify whether MA users have more quantifiable dental disease and report having more dental problems than nonusers and establish the influence of mode of MA administration on oral health outcomes. METHODS: Participating physicians provided comprehensive medical and oral assessments for adults dependent on MA (n=301). Trained interviewers collected patients' self-reports regarding oral health and substance-use behaviors. The authors used propensity score matching to create a matched comparison group of nonusers from participants in the the Third National Health and Nutrition Examination Survey (NHANES III). RESULTS: Dental or oral disease was one of the most prevalent (41.3 percent) medical cormorbidities in MA users who otherwise were generally healthy. On average, MA users had significantly more missing teeth than did matched NHANES III control participants (4.58 versus 1.96, P<.001) and were more likely to report having oral health problems (P<.001). Significant subsets of MA users expressed concerns with their dental appearance (28.6 percent), problems with broken or loose teeth (23.3 percent) and tooth grinding (bruxism) or erosion (22.3 percent). The intravenous use of MA was significantly more likely to be associated with missing teeth than was smoking MA (odds ratio=2.47; 95 percent confidence interval=1.3-4.8). CONCLUSIONS: Overt dental disease is one of the key distinguishing comorbidities in MA users. MA users have demonstrably higher rates of dental disease and report long-term unmet oral health needs. Contrary to common perception, users who smoke or inhale MA have lower rates of dental disease than do those who inject the drug. Many MA users are concerned with the cosmetic aspects of their dental disease, and these concerns could be used as behavioral triggers for targeted interventions. CLINICAL IMPLICATIONS: Dental disease may provide a temporally stable MA-specific medical marker with discriminant utility in identifying MA users. Dentists can play a crucial role in the early detection of MA use and participate in the collaborative care of MA users.
Authors: B A Dye; R Nowjack-Raymer; L K Barker; J H Nunn; J G Steele; S Tan; B G Lewis; E D Beltran-Aguilar Journal: J Public Health Dent Date: 2008 Impact factor: 1.821
Authors: E Lichtenstein; J F Hollis; H H Severson; V J Stevens; T M Vogt; R E Glasgow; J A Andrews Journal: Addict Behav Date: 1996 Nov-Dec Impact factor: 3.913
Authors: Tarnjit Saini; Paul C Edwards; Nicole S Kimmes; Lucinda R Carroll; John W Shaner; Frank J Dowd Journal: Oral Health Prev Dent Date: 2005 Impact factor: 1.256
Authors: Debra A Murphy; Lauren Harrell; Rachel Fintzy; Thomas R Belin; Alexis Gutierrez; Steven J Vitero; Vivek Shetty Journal: J Behav Health Serv Res Date: 2016-10 Impact factor: 1.505
Authors: Cindy L Ehlers; Ian R Gizer; David A Gilder; Kirk C Wilhelmsen Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2011-08-02 Impact factor: 3.568
Authors: Niklas Rommel; Nils H Rohleder; Stefan Wagenpfeil; Roland Härtel-Petri; Frederic Jacob; Klaus-Dietrich Wolff; Marco R Kesting Journal: Clin Oral Investig Date: 2015-07-15 Impact factor: 3.573
Authors: Glen R Hanson; Shawn McMillan; Kali Mower; Carter T Bruett; Llely Duarte; Sri Koduri; Lilliam Pinzon; Matt Warthen; Ken Smith; Huong Meeks; Bryan Trump Journal: J Am Dent Assoc Date: 2019-05-20 Impact factor: 3.634
Authors: Vivek Shetty; Lauren Harrell; Debra A Murphy; Steven Vitero; Alexis Gutierrez; Thomas R Belin; Bruce A Dye; Vladimir W Spolsky Journal: J Am Dent Assoc Date: 2015-12 Impact factor: 3.634